GET DAILY SIGNALSWhy Is MacroGenics (MGNX) Stock Down -9.33% Today?
Key Takeaways
- Shares of MacroGenics fell about 9.33% in Monday's session, trading near $2.04 after closing Friday at $2.25.
- Primary catalyst: A continuation of the post-data selloff that began Friday, after the market delivered a "sell the news" response to interim Phase 1 results for its lead B7-H3 antibody-drug conjugate, MGC026.
- Secondary drivers: Profit-taking following a steep run-up in the shares, persistent operational cash burn, and profit-booking by momentum traders.
- Broader context: The decline is unfolding amid renewed caution across small-cap and clinical-stage biotechnology names.
- What traders are watching: Upcoming third-quarter results, further pipeline updates, and whether the stock can stabilize above recent lows.
- For deeper analysis, explore MacroGenics Price Targets, Earnings, and Forecast pages.
- Discover AI-driven trading strategies in the Trending AI Robots section.
Opening Summary
MGNX, MacroGenics, Inc., is a Rockville, Maryland-based clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer. On Monday, shares were down roughly 9.33%, trading near $2.04 versus Friday's closing price of $2.25. The decline extends a sharp pullback that began late last week, when the stock dropped about 38% in a single session following its clinical data presentations at the 2026 ESMO Congress. The immediate driver cited by markets is continued selling pressure in the wake of that data, as investors reassess the risk-reward profile of the company's lead oncology pipeline.
Post-ESMO "Sell the News" Continues
The dominant force behind MGNX's slide is the market's reaction to interim Phase 1 data for MGC026, a B7-H3-directed antibody-drug conjugate (ADC). At ESMO 2026, the company reported a 27% best overall response rate in heavily pretreated head and neck squamous cell carcinoma patients, alongside a manageable safety profile with no interstitial lung disease or ocular toxicity. However, the readout also showed a 48% rate of Grade 3 or higher treatment-related adverse events, driven primarily by anemia and neutropenia.
Although the efficacy signals were described as encouraging, they did not meet the elevated expectations built into the stock after a months-long rally. The resulting "sell the news" dynamic, which began Friday with an outsized volume-driven drop, is continuing into Monday's session as investors digest the durability and tolerability of the data.
Profit-Taking After a Steep Rally
MGNX had climbed dramatically off its 52-week low of $1.30, more than doubling at its highs earlier this year as optimism around its ADC pipeline and an improved cash position took hold. That appreciation left the shares vulnerable to profit-taking once the long-awaited MGC026 data arrived. With momentum and retail-driven flows having played a role in the run-up, the unwind has been amplified as short-term traders exit positions and institutional holders reassess exposure to a still-unprofitable, clinical-stage company.
Financial Runway Versus Ongoing Cash Burn
MacroGenics has strengthened its balance sheet through the roughly $122.5 million sale of its GMP manufacturing operations to Bora Pharmaceuticals and partnership milestones, supporting an estimated pro forma cash position in the hundreds of millions of dollars. Yet the company continues to post meaningful operational losses, with a quarterly net loss from continuing operations exceeding $69 million in its most recent report. This tension—a longer runway versus persistent core losses—has added to the cautious sentiment weighing on the shares.
Market Context and Trading Activity
Friday's decline was accompanied by exceptionally heavy volume, with turnover running several times the stock's average daily volume, signaling institutional distribution rather than isolated retail selling. Monday's continuation move suggests that sellers remain in control, with the shares breaking decisively below prior support levels established during the stock's earlier run. The move appears idiosyncratic to MGNX, diverging from the broader market and reflecting company-specific catalyst risk in a clinical-stage biotech rather than a broad index-driven selloff.
What Comes Next for MacroGenics
Looking ahead, investors will focus on the company's third-quarter earnings release and management commentary on its cash runway and spending plans. Key catalysts include updated Phase 1 data for MGC026 expected in mid-2027, the planned initiation of a front-line combination study with pembrolizumab in early 2027, and further readouts from the lorigerlimab program. Risks include the potential for disappointing or delayed clinical data, continued cash burn, and the possibility of additional insider or institutional selling. The stock's ability to stabilize and consolidate near current levels will be closely watched as a signal of whether the selloff has run its course.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's strongest-performing artificial intelligence trading bots. Tickeron offers hundreds of AI bots covering thousands of tickers, but only those demonstrating the most robust performance under current market conditions are featured in this section. These bots vary by trading strategy, timeframe, performance metrics, and the symbols they trade. Explore the Trending AI Robots page to see which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MGNX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 23, 2026
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 34 cases where MGNX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for MGNX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 67 cases where MGNX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
Following a +4.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in 229 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MGNX as a result. In 83 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for MGNX turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 46 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
MGNX moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MGNX crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for MGNX entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. MGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.343) is normal, around the industry mean (3.035). P/E Ratio (-10.227) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (10.770) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (1.477) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the discovery and development of monoclonal antibody-based therapeutics
Industry Biotechnology
Advertisement